NCT00698282

Brief Summary

The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
47

participants targeted

Target at P50-P75 for phase_1 healthy

Timeline
Completed

Started Aug 2008

Shorter than P25 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 16, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 17, 2008

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2008

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2008

Completed
Last Updated

December 1, 2010

Status Verified

November 1, 2010

Enrollment Period

2 months

First QC Date

June 16, 2008

Last Update Submit

November 30, 2010

Conditions

Outcome Measures

Primary Outcomes (2)

  • Adverse events

    All the time

  • Plasma drug concentration

    Every hour

Secondary Outcomes (1)

  • Clinical chemistry

    day 1 and 9

Study Arms (3)

1

EXPERIMENTAL
Drug: AZD1981

2

EXPERIMENTAL
Drug: AZD1981

3

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Oral tablet, 250 mg single dose

1
3

Eligibility Criteria

Age20 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy Japanese and Caucasian males

You may not qualify if:

  • Other clinically relevant disease or disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research Site

Berkshire, United Kingdom

Location

MeSH Terms

Interventions

AZD1981

Study Officials

  • Elizabeth Hancox

    Europe Chiltern International Ltd, Berkshire, UK

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 16, 2008

First Posted

June 17, 2008

Study Start

August 1, 2008

Primary Completion

October 1, 2008

Study Completion

October 1, 2008

Last Updated

December 1, 2010

Record last verified: 2010-11

Locations